{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-029872","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.588933+00:00","generated_at":"2026-06-17T02:06:30.387821+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Jasper Therapeutics adds CEO vesting acceleration, extends chairperson term","bullets":["Chairperson William Lis term extended to Mar 15, 2024; annual cash comp reduced to $125K from $250K effective Apr 1, 2023.","CEO Ronald Martell: if terminated without cause/good reason within 24 months post-Change in Control, receives 18 months base salary plus full equity vesting.","Change in Control defined by reference to Jasper's Severance Plan; amendments effective April 13, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-029872","json":"https://secwatch.observer/filing/0001213900-23-029872.json","markdown":"https://secwatch.observer/filing/0001213900-23-029872.md","text":"https://secwatch.observer/filing/0001213900-23-029872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023029872/0001213900-23-029872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023029872/ea176965-8k_jasperthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:06:30.387821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}